Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
AstraZeneca |
---|---|
Information provided by: | AstraZeneca |
ClinicalTrials.gov Identifier: | NCT00640601 |
A Canadian Multicentre, Open-label, Prospective Long-term Study Evaluating the Clinical Benefit and Effectiveness of SEROQUEL XR® (Quetiapine Fumarate Extended-Release Tablets) in Subjects with Schizophrenia.
Condition | Intervention | Phase |
---|---|---|
Schizophrenia |
Drug: Quetiapine Fumarate Extended- Release |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Efficacy Study |
Official Title: | A Canadian Multicentre, Open-Label, Prospective Long-Term Study Evaluating the Clinical Benefit and Effectiveness of SEROQUEL XR® (Quetiapine Fumarate Extended-Release Tablets) in Subjects With Schizophrenia |
Estimated Enrollment: | 500 |
Study Start Date: | March 2008 |
Estimated Study Completion Date: | July 2010 |
Estimated Primary Completion Date: | April 2010 (Final data collection date for primary outcome measure) |
Ages Eligible for Study: | 18 Years to 65 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
A patient with Diabetes Mellitus (DM) fulfilling one of the following criteria:
Note: If a diabetic patient meets one of these criteria the patient is to be excluded even if the treating physician believes the patient is stable and can participate in the study.
Contact: Canada Clinical Study Information | (905) 804-5841 | duncan.jewell@astrazeneca.com |
Canada | |
Research Site | Recruiting |
QUEBEC, Canada | |
Canada, Alberta | |
Research Site | Not yet recruiting |
CALGARY, Alberta, Canada | |
Research Site | Not yet recruiting |
CLARESHOLM, Alberta, Canada | |
Research Site | Not yet recruiting |
RED DEER, Alberta, Canada | |
Canada, British Columbia | |
Research Site | Recruiting |
VANCOUVER, British Columbia, Canada | |
Research Site | Not yet recruiting |
VICTORIA, British Columbia, Canada | |
Canada, Manitoba | |
Research Site | Not yet recruiting |
WINNIPEG, Manitoba, Canada | |
Canada, Newfoundland and Labrador | |
Research Site | Recruiting |
ST JOHN'S, Newfoundland and Labrador, Canada | |
Canada, Nova Scotia | |
Research Site | Recruiting |
SYDNEY, Nova Scotia, Canada | |
Canada, Ontario | |
Research Site | Recruiting |
BELLEVILLE, Ontario, Canada | |
Research Site | Recruiting |
BRANTFORD, Ontario, Canada | |
Research Site | Recruiting |
MARKHAM, Ontario, Canada | |
Research Site | Recruiting |
KINGSTON, Ontario, Canada | |
Research Site | Recruiting |
LONDON, Ontario, Canada | |
Research Site | Recruiting |
CHATHAM, Ontario, Canada | |
Research Site | Recruiting |
MISSISSAUGA, Ontario, Canada | |
Research Site | Recruiting |
NEWMARKET, Ontario, Canada | |
Research Site | Recruiting |
OAKVILLE, Ontario, Canada | |
Research Site | Recruiting |
ORLEANS, Ontario, Canada | |
Research Site | Recruiting |
SUDBURY, Ontario, Canada | |
Research Site | Recruiting |
TORONTO, Ontario, Canada | |
Research Site | Not yet recruiting |
WELLAND, Ontario, Canada | |
Canada, Quebec | |
Research Site | Recruiting |
GATINEAU, Quebec, Canada | |
Research Site | Recruiting |
GREENFIELD PARK, Quebec, Canada | |
Research Site | Not yet recruiting |
LEVIS, Quebec, Canada | |
Research Site | Recruiting |
MONTREAL, Quebec, Canada | |
Research Site | Not yet recruiting |
ROUYN-NORANDA, Quebec, Canada | |
Research Site | Recruiting |
SHERBROOKE, Quebec, Canada | |
Research Site | Recruiting |
VERDUN, Quebec, Canada | |
Canada, Saskatchewan | |
Research Site | Not yet recruiting |
PRINCE ALBERT, Saskatchewan, Canada | |
Research Site | Not yet recruiting |
SASKATOON, Saskatchewan, Canada |
Principal Investigator: | Pierre Chue, MD | University of Alberta |
Study Chair: | Kristina Timdahl, MD | AstraZeneca R&DSodertalje, Sweden |
Responsible Party: | AstraZeneca ( Hans Eriksson - Medical Science Director ) |
Study ID Numbers: | D1443L00025 |
Study First Received: | March 17, 2008 |
Last Updated: | August 29, 2008 |
ClinicalTrials.gov Identifier: | NCT00640601 |
Health Authority: | Canada: Health Canada |
Seroquel schizophrenia Extended Release |
Schizophrenia Quetiapine Mental Disorders Psychotic Disorders Schizophrenia and Disorders with Psychotic Features |
Tranquilizing Agents Therapeutic Uses Physiological Effects of Drugs Psychotropic Drugs |
Central Nervous System Depressants Antipsychotic Agents Central Nervous System Agents Pharmacologic Actions |